Hippo Pathway-independent Restriction of TAZ and YAP by Angiomotin

被引:316
|
作者
Chan, Siew Wee [1 ]
Lim, Chun Jye [1 ]
Chong, Yaan Fun [1 ]
Pobbati, Ajaybabu V. [1 ]
Huang, Caixia [1 ]
Hong, Wanjin [1 ,2 ]
机构
[1] Inst Mol & Cell Biol, Canc & Dev Cell Biol Div, Singapore 138673, Singapore
[2] Natl Univ Singapore, Dept Biochem, Singapore 119077, Singapore
关键词
YES-ASSOCIATED PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; CELL CONTACT INHIBITION; ORGAN SIZE CONTROL; WW DOMAIN; ONCOGENIC TRANSFORMATION; GROWTH-CONTROL; TRANSCRIPTION; BINDING; CANCER;
D O I
10.1074/jbc.C110.212621
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Hippo pathway restricts the activity of transcriptional co-activators TAZ and YAP by phosphorylating them for cytoplasmic sequestration or degradation. In this report, we describe an independent mechanism for the cell to restrict the activity of TAZ and YAP through interaction with angiomotin (Amot) and angiomotin-like 1 (AmotL1). Amot and AmotL1 were robustly co-immunoprecipitated with FLAG-tagged TAZ, and their interaction is dependent on the WW domain of TAZ and the PPXY motif in the N terminus of Amot. Amot and AmotL1 also interact with YAP via the first WW domain of YAP. Overexpression of Amot and AmotL1 caused cytoplasmic retention of TAZ and suppressed its transcriptional outcome such as the expression of CTGF and Cyr61. Hippo refractory TAZ mutant (S89A) is also negatively regulated by Amot and AmotL1. HEK293 cells express the highest level of Amot and AmotL1 among nine cell lines examined, and silencing the expression of endogenous Amot increased the expression of CTGF and Cyr61 either at basal levels or upon overexpression of exogenous S89A. These results reveal a novel mechanism to restrict the activity of TAZ and YAP through physical interaction with Amot and AmotL1.
引用
收藏
页码:7018 / 7026
页数:9
相关论文
共 50 条
  • [31] THE BIOLOGY OF YAP/TAZ: HIPPO SIGNALING AND BEYOND
    Piccolo, Stefano
    Dupont, Sirio
    Cordenonsi, Michelangelo
    PHYSIOLOGICAL REVIEWS, 2014, 94 (04) : 1287 - 1312
  • [32] YAP and TAZ: a nexus for Hippo signaling and beyond
    Hansen, Carsten Gram
    Moroishi, Toshiro
    Guan, Kun-Liang
    TRENDS IN CELL BIOLOGY, 2015, 25 (09) : 499 - 513
  • [33] Hippo-YAP/TAZ signaling in angiogenesis
    Park, Jeong Ae
    Kwon, Young-Guen
    BMB REPORTS, 2018, 51 (03) : 157 - 162
  • [34] Hippo-Independent Regulation of Yki/Yap/Taz: A Non-canonical View
    Cho, Yong Suk
    Jiang, Jin
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [35] Angiomotin family proteins in the Hippo signaling pathway
    Wang, Yu
    Yu, Fa-Xing
    BIOESSAYS, 2024, 46 (08)
  • [36] Role of Hippo-YAP1/TAZ pathway and its crosstalk in cardiac biology
    Chen, Xiaoqing
    Yuan, Wenchang
    Li, Yilang
    Luo, Jiandong
    Hou, Ning
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (13): : 2454 - 2463
  • [37] A novel role of Hippo-Yap/TAZ signaling pathway in lymphatic vascular development
    Cha, Boksik
    Moon, Sungjin
    Kim, Wantae
    BMB REPORTS, 2021, 54 (06) : 285 - 294
  • [38] The Hippo-YAP/TAZ pathway mediates geranylgeranylation signaling in breast cancer progression
    Lin, Qiong
    Yang, Wannian
    MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (03)
  • [39] Pro-Invasive Activity of the Hippo Pathway Effectors YAP and TAZ in Cutaneous Melanoma
    Nallet-Staub, Flore
    Marsaud, Veronique
    Li, Ling
    Gilbert, Cristele
    Dodier, Sophie
    Bataille, Veronique
    Sudol, Marius
    Herlyn, Meenhard
    Mauviel, Alain
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (01) : 123 - 132
  • [40] Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review
    Crawford, James J.
    Bronner, Sarah M.
    Zbieg, Jason R.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28 (12) : 867 - 873